U.S. Markets closed

Align Rides on Firm Global Footprint Despite Fierce Rivalry

Zacks Equity Research

On Apr 8, we issued an updated research report on Align Technology, Inc. ALGN. The stock carries a Zacks Rank #3 (Hold).

Notably, Align Technology manufactures and markets clear aligner therapy, intra-oral scanners and CAD/CAM (computer-aided design and manufacturing) digital services used in dentistry, orthodontics and dental records storage.

Shares of the company have outperformed its industry over the past three months. The stock has rallied 13.8% compared with the industry's 7% growth. 

Align Technology exited the fourth quarter of 2018 on a solid note. We are upbeat about the continued strength in Invisalign volumes. In North America, the company consistently witnessed an expanding GP dentist customer base along with a steady uptake of Invisalign by orthodontists.

We are also encouraged by the company’s solid performance in the Europe, Middle East and Africa and Asia-Pacific markets. The company is also witnessing sturdy worldwide teen case growth. It launched the Invisalign with mandibular advancement feature in the United States during the fourth quarter, post the receipt of an FDA approval last October. Per management, through the end of the quarter under review, more than 17,000 teenagers used the product, led by strength in China, Canada, France and Spain.

Align Technology, Inc. Price

Align Technology, Inc. Price | Align Technology, Inc. Quote

Moreover, robust revenues from the iTero scanner contributed substantially. The company has been gaining traction from the shipments of the iTero Element intraoral scanner to China. Also, the company has begun manufacturing the iTero Element intraoral scanner in China after securing a Certificate of Medical Device Registration and Certificate of Production from the China Food and Drug Administration (CFDA). Align Technology is witnessing improved sales within the Scanner and Services business on the global front including Italy, Japan and China.

We are also optimistic about the company’s expansion of the iTero Element portfolio with the launch of iTero Element 2 and iTero Element Flex scanners in the United States and a majority of European countries ranging from France, Germany, Italy, Spain to the United Kingdom. The company is benefiting from an impressive response for the product, particularly regarding the restorative GP dentists in North America.

On the flip side, an adverse foreign exchange translation persists to raise concerns for Align Technology’s overseas operations. Also, escalating costs and expenses are weighing on its margins. Moreover, a tough competitive landscape and other macroeconomic headwinds pose a threat to the stock.

Key Picks

A few better-ranked stocks in the broader medical space are ABIOMED, Inc., ABMD, Varian Medical Systems, Inc. VAR and Masimo, Inc. MASI, each currently carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

ABIOMED’s long-term earnings growth rate is expected at 27.67%.

Varian’s long-term earnings growth rate is projected at 8%.

Masimo’s long-term earnings are estimated to grow 15.60%.

Today's Best Stocks from Zacks

Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.

This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.

See their latest picks free >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
ABIOMED, Inc. (ABMD) : Free Stock Analysis Report
 
Masimo Corporation (MASI) : Free Stock Analysis Report
 
Varian Medical Systems, Inc. (VAR) : Free Stock Analysis Report
 
Align Technology, Inc. (ALGN) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research